Olezarsen · Tryngolza
RNA / oligonucleotide
Evidence outlook
Approved: Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Hypertriglyceridemia · Phase 3 · investigational in the US
Also approved (2)
- Adjunct to diet in adult patients for the treatment of FCS (Notice of Compliance date from the CDA-AMC review; sponsor Theratechnologies Inc.)
- Adjunct to diet in adults with genetically confirmed familial chylomicronemia syndrome; marketing authorisation holder Swedish Orphan Biovitrum AB (Sobi)
Company guidance: regulatory decision expected fourth quarter of 2026 (Ionis Pharmaceuticals, 9 Nov 2026). “FCS launch outside the U.S. underway; received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for sHTG (sHTG fasting triglyceride levels of ≥880 mg/dL [≥10 mmol/L]), paving the way to bring TRYNGOLZA to sHTG patients across Europe with a final approval decision expected in the fourth quarter of 2026” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05079919 NCT05079919 · Severe Hypertriglyceridemia This was a randomized, triple-blind, placebo-controlled trial of 617 patients. Both tested doses of olezarsen produced large reductions in triglycerides, the physiological measure that defines this disease, compared with placebo, with strong statistical significance. Registry: NCT05079919 | 3 | Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6) 2024-10-22 | Placebo-adjusted LSM % change in fasting triglycerides at 6 months (CORE-TIMI 72a, NCT05079919, n=617): olezarsen 50 mg -62.9% (95% CI -72.2 to -53.6, p<0.001); olezarsen 80 mg -72.2% (95% CI -81.4 to -63.1, p<0.001). | Reliable signal | link ↗ |
View 1 more trial
NCT05552326 NCT05552326 · Severe Hypertriglyceridemia This was a randomized, triple-blind, placebo-controlled trial of 446 patients. Both tested doses of olezarsen produced large, statistically significant reductions in triglycerides compared with placebo, replicating the result seen in a related trial. Registry: NCT05552326 | 3 | Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6) 2024-12-17 | Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other APOC3 drugs
Plozasiran, HRS-7249, ION775, RBD5044, RN0361 and 2 more. Compare all 8 APOC3 drugs
7 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Familial Chylomicronemia Syndrome: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Olezarsen (Tryngolza): this drug | Approved | RNA / oligonucleotide | APOC3 | Partial signal | NCT04568434: Fasting triglycerides, percent change at 6 months vs placebo: olezarsen 80 mg -43.5 percentage points (95% CI -69.1 to -17.9), P<0.001 (met); olezarsen 50 mg -22.4 percentage points (95% CI -47.2 to 2.5), P = 0.08 (not met). Acute pancreatitis: 11 episodes on placebo vs 1 in each olezarsen group by week 53. | |
| Plozasiran (Redemplo) | Approved | RNA / oligonucleotide | APOC3 | Partial signal | NCT05089084: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG) (Baseline, Month 10): ARO-APOC3 (Plozasiran) 25 mg -80.1% (IQR -89.9 to -61) | ARO-APOC3 (Plozasiran) 50 mg -77.6% (IQR -87.7 to -48.6) vs Placebo (Pooled) -17.1% (IQR -49.1 to 47) | |
| Volanesorsen (Waylivra) | Phase 3 | RNA / oligonucleotide | APOC3 mRNA | Reliable signal | NCT02211209: Percent Change in Fasting Triglycerides (TG) From Baseline to Month 3 (Baseline to 3 months): Placebo 17.6 percent change (95% CI -4 to 39.2) | Volanesorsen -76.5 percent change (95% CI -97.4 to -55.5) | |
| CS-121 | Phase 1 | Gene therapy / editing | APOC3 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tryngolza (Olezarsen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2028 (1)
February 2028 (1)
What to watch
2030 (1)
August 2030 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent